araag2/HINT huggingface dataset:
Clinical trial NCT00377637 (phase 3, status: completed)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: mycophenolate mofetil (mmf), cyclophosphamide, azathioprine, placebo to azathioprine, placebo to mycophenolate mofetil, corticosteroid
SMILES: COC(=O)\C=C\C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O, CN1C=NC(=C1SC1=NC=NC2=C1NC=N2)[N+]([O-])=O, COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  male or female patients, 12-75 years of age;

          -  diagnosis of systemic lupus erythematosus;

          -  kidney biopsy within 6 months of study, with histological diagnosis of lupus
             nephritis;

          -  laboratory evidence of active nephritis.

        Exclusion Criteria:

          -  continuous dialysis starting >2 weeks before randomization into induction phase,
             and/or with an anticipated duration of >8 weeks;

          -  previous or planned kidney transplant;

          -  other clinically significant active medical conditions.
Clinical trial NCT01281839 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: tmc435, placebo, peginterferon alpha-2a (pegifn alpha-2a), ribavirin (rbv)
SMILES: [H]\C1=C([H])\[C@]2([H])C[C@]2(N=C(O)[C@]2([H])C[C@]([H])(C[C@@]2([H])C(=O)N(C)CCCC1)OC1=C2C=CC(OC)=C(C)C2=NC(=C1)C1=NC(=CS1)C(C)C)C(O)=NS(=O)(=O)C1CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Genotype 1 hepatitis C infection (confirmed at screening)

          -  Have previously received peginterferon-based therapy for at least 24 weeks with
             documented HCV RNA at last measurement and relapsed within 1 year of last taking
             medication

          -  Liver biopsy within 3 years before screening (or between the screening and baseline
             visit) showing chronic hepatitis C infection

          -  Must agree to use 2 forms of effective contraception throughout study (both males and
             females)

        Exclusion Criteria:

          -  Infection with HIV or non-genotype 1 hepatitis C

          -  Liver disease not related to hepatitic C infection

          -  Hepatic decompensation

          -  Significant laboratory abnormalities or other active diseases

          -  Pregnant or planning to become pregnant
Clinical trial NCT00680745 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, glimepiride, metformin hydrochloride, pioglitazone hydrochloride, rosiglitazone
SMILES: CN(C)C(=N)NC(N)=N, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CN(C)C(=N)NC(N)=N, CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1, CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes

          -  Treatment with a stable sulphonylurea monotherapy dose that is at least half the
             maximal recommended dose for a minimum of 8 weeks prior to study

          -  Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Hepatic (liver) impairment

          -  Renal (kidney) failure or dysfunction
Clinical trial NCT00596791 (phase 3, status: completed)
Conditions: ocular hypertension, open-angle glaucoma
ICD codes: H40.053, H40.051, H40.052, H40.059, H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131
Drugs: tafluprost
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a diagnosis of ocular hypertension or open angle glaucoma for which the
             patient has been using latanoprost 0.005% as his/her prior medication. - Evaluable
             patients must have ocular surface related symptoms and/or signs with their prior
             medication.
Clinical trial NCT00113165 (phase 3, status: completed)
Conditions: epilepsy, epilepsy, partial
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801, G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: lamictal extended-release
SMILES: NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of epilepsy with partial seizures for more than 24 weeks.

          -  Must experience at least 8 partial seizures during an 8-week Baseline Phase.

          -  Must currently be receiving treatment with a stable regimen of one or two
             antiepileptic drugs for at least four weeks.

          -  Patient or parent/caregiver must be willing and able to maintain a written daily
             seizure diary.

        Exclusion criteria:

          -  Previous treatment with lamotrigine.

          -  Exhibits any primary generalized seizures.

          -  Receiving treatment with felbamate or currently following the ketogenic diet.

          -  Pregnant, breastfeeding, or planning to become pregnant.
Clinical trial NCT01008410 (phase 3, status: completed)
Conditions: proctitis, proctosigmoiditis
ICD codes: K62.7, K51.20, K51.213, K51.214, K51.211, K51.212, K51.218
Drugs: budesonide, placebo
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Voluntarily sign written informed consent.

          -  Male or non-pregnant and non-lactating females.

          -  Confirmed diagnosis (by endoscopy procedure) of active, mild to moderate UP or UPS,
             with disease extending at least 5 centimeters (cm) but no further than 40 cm from the
             anal verge.

          -  Must possess a baseline Modified Mayo Disease Activity Index (MMDAI) score between 5
             and 10.

        Exclusion Criteria:

          -  History or current diagnosis of Crohn's disease and indeterminate colitis.

          -  Prior gastrointestinal surgery except appendectomy and hernia.

          -  Concomitant active gastrointestinal disease or distortion of intestinal anatomy.

          -  History of diverticulitis, collagenous colitis, celiac disease, recurrent pancreatic
             or known gallbladder disease.

          -  Uncontrolled, previously diagnosed type 1 or 2 diabetes mellitus.

          -  Uncontrolled abnormal thyroid function.

          -  Unstable significant cardiovascular, endocrine, neurologic or pulmonary disease.

          -  Hemoglobin levels less than (<) 7.5 grams /deciliter (g/dL).

          -  History of sclerosing cholangitis, cirrhosis, or hepatic impairment.

          -  Renal disease manifested by greater than (>) 2.0 milligrams/deciliter (mg/dL) serum
             creatinine.

          -  History of avascular hip necrosis, active tuberculosis, ocular herpes simplex or
             ocular varicella zoster, malignant disease, and human immunodeficiency virus (HIV) or
             hepatitis B or C.

          -  Adrenal insufficiency.

          -  Active systemic or cutaneous infection or toxic megacolon, fistula, perforation or
             abscess.

          -  History of uncontrolled psychiatric disorders or seizure disorders.

          -  History of asthma requiring ongoing use of inhaled steroids.

          -  Recent history of drug or alcohol abuse.

          -  Positive stool test for bacterial pathogens, Clostridium difficile toxin, or ovum and
             parasites.

          -  Vaccination within 28 days prior to randomization.

          -  Allergies to budesonide or to any other items used in its preparation.

          -  Participation in another clinical trial in the past 30 days.

          -  Pregnant or at risk of pregnancy.

          -  Taking a prohibited medication. Some medications to treat UP/UPS are prohibited during
             participation in the study, including laxatives and anti-diarrhea medications;
             however, oral 5-ASA agents at doses up to 4.8 g/day and daily fiber supplements are
             allowed. Other medications (e.g., antibiotics, anti-seizure and anti-coagulant
             medicines) are also prohibited.
Clinical trial NCT00252785 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: budesonide/formoterol, budesonide, theophylline
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, CN1C2=C(NC=N2)C(=O)N(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of asthma with a documented history of at least 6 months duration prior to
             Visit 1

          -  Prescribed daily use of an IGCS for >=12 weeks prior to Visit 1. The dose of IGCS must
             be 400 to 800 µg/day of Pulmicort® Turbuhaler® or corresponding dose of IGCS. The
             prescribed dose of IGCS should be constant for at least 4 weeks prior to Visit 1

          -  Prescribed daily use of sustained release theophylline for at least 8 weeks prior to
             Visit 1, or confirmed steady-state blood theophylline concentrations within the
             effective range (5-15 µg/mL) during 8 weeks prior to Visit 1. The prescribed dose of
             theophylline should be constant (400 mg/day) for at least 4 weeks prior to Visit 1

        Exclusion Criteria:

          -  Any significant disease or disorder that may jeopardize the safety of the patient

          -  Respiratory infection, judged by the investigator(s) as an infection affecting the
             asthma, within 4 weeks prior to Visit 1

          -  Treatment with oral, parenteral or rectal GCS within 4 weeks prior to Visit 1

        Additional inclusion and exclusion criteria will be evaluated by the Investigator
Clinical trial NCT00267683 (phase 3, status: terminated)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin aspart, glibenclamide
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, COC1=C(C=C(Cl)C=C1)C(=O)NCCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NC1CCCCC1
Reason stopped: 
    this trial was terminated due to low recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Diet therapy for at least 12 weeks, or diet therapy and oral hypoglycaemic agent(s)
             other than SU agents for at least 12 weeks

          -  No previous treatment with insulin and/or SU agents

          -  HbA1c between 7.5% and 10.0%

          -  Body Mass Index (BMI) below 30.0 kg/m2

        Exclusion Criteria:

          -  Proliferative retinopathy or maculopathy requiring acute treatment

          -  Impaired hepatic function

          -  Impaired renal function

          -  Cardiac diseases

          -  Uncontrolled hypertension

          -  Known hypoglycaemia unawareness or recurrent major hypoglycaemia

          -  Current treatment with systemic corticosteroids
Clinical trial NCT01486940 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin detemir, insulin aspart, insulin nph, human soluble insulin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes for at least 12 months

          -  Current treatment with any basal/bolus regimen or any biphasic insulin treatment for
             at least 6 months

          -  BMI below or equal to 35 kg/m^2

          -  HbA1c below or equal to 12%

        Exclusion Criteria:

          -  Proliferative retinopathy or maculopathy requiring acute treatment

          -  Recurrent major hypoglycaemia that may interfere with trial participation (as judged
             by the Investigator)

          -  Subjects with known hypoglycaemic unawareness as judged by the Investigator
Clinical trial NCT00417209 (phase 3, status: completed)
Conditions: pancreatic neoplasms
ICD codes: C25.3
Drugs: larotaxel (xrp9881), 5-fluorouracil, capecitabine
SMILES: CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)C3=CC=CC=C3)[C@H]3[C@]4(C[C@H]4C[C@H]4OC[C@@]34OC(C)=O)C1=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced (non operable in a curative intent, locally recurrent or metastatic disease)
             Cytologically or histologically proven epithelial cancer (adenocarcinoma) of the
             exocrine pancreas.

          -  Patient must be previously treated with a systemic gemcitabine based regimen

          -  Adequate bone marrow, kidney and liver functions

        Exclusion Criteria:

          -  ECOG performance status (PS) of 2-3-4.

          -  Prior locoregional radiotherapy for pancreatic cancer.

          -  Symptomatic brain metastases or leptomeningeal disease.

          -  Any serious intercurrent infections, uncontrolled cardiac or gastro-intestinal
             diseases.

          -  Other concurrent malignancy

          -  Other protocol-defined exclusion/inclusion criteria may apply
Clinical trial NCT00614380 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: telmisartan/amlodipine 40/5 mg fixed combination, telmisartan/amlodipine 80/5 mg fixed combination
SMILES: CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O, CCCC1=NC2=C(C=C(C=C2C)C2=NC3=CC=CC=C3N2C)N1CC1=CC=C(C=C1)C1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. patients aged at least 18 years

          2. diagnosis of essential hypertension and blood pressure not adequately controlled
             before enrolment in the preceding trial.

          3. failure to respond to six weeks treatment with Amlodipine 5 mg in the run-in period of
             the preceding trial.

        Exclusion Criteria:

          1. pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or
             are not practising acceptable means of birth control or do not plan to continue using
             acceptable means of birth control throughout the study

          2. development of any medical condition in the preceding trial that in the investigator's
             opinion could be worsened by treatment with either Telmisartan 40 mg/Amlodipine 5 mg
             or Telmisartan 80 mg/Amlodipine 5 mg

          3. discontinuation from the preceding trial because of any adverse event or any other
             reason

          4. known or suspected secondary hypertension

          5. mean seated Systolic Blood Pressure => 180 mmHg and/or mean seated Diastolic Blood
             Pressure => 120 mmHg at any visit
Clinical trial NCT00636168 (phase 3, status: completed)
Conditions: high risk stage iii melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ipilimumab, placebo
SMILES: COC1=CC=CC=C1OCC(O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Complete and adequate resection of Stage III melanoma with histologically confirmed
             melanoma metastatic to lymph node

          -  Disease-free

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1

          -  Randomization within 12 weeks of surgery

        Exclusion Criteria:

          -  Prior therapy for melanoma except surgery

          -  Auto-immune disease
Clinical trial NCT01459588 (phase 3, status: completed)
Conditions: dry eye syndromes
ICD codes: H04.121, H04.122, H04.123, H04.129
Drugs: carboxymethylcellulose based eye drop formulation a, carboxymethylcellulose based eye drop formulation b, carboxymethylcellulose based preservative-free lubricant eye drops, carboxymethylcellulose based lubricant eye drops
SMILES: OCC(O)CO
Eligibility criteria:

        Inclusion Criteria:

          -  Dry eyes

          -  Current use of eye drops for dry eye at least twice daily, on average for at least 3
             months

        Exclusion Criteria:

          -  Cataract, laser-assisted in situ keratomileusis (LASIK), or photorefractive
             keratectomy (PRK) surgery in the last 12 months

          -  Need to wear contact lenses during the study, or has worn contact lenses in the last 6
             months

          -  Active ocular allergy
Clinical trial NCT00376272 (phase 3, status: completed)
Conditions: atrial fibrillation
ICD codes: I48.0, I48.21, I48.91, I48.11, I48.19, I48.20
Drugs: valsartan, placebo
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients >=40 years of age

          2. Sinus rhythm

          3. At least two ECG documented episodes of symptomatic AF in the previous 6 months or
             After a successful cardioversion for AF performed between 14 days and 48 hours before
             randomization

          4. At least one of the following underlying cardiovascular diseases/comorbidities:

               -  heart failure/documented history of LV dysfunction (defined as an EF <40%)

               -  history of hypertension >=6 months with/without LVH

               -  Type II diabetes mellitus

               -  documented history of stroke or peripheral vascular disease

               -  documented history of coronary artery disease

               -  lone atrial fibrillation with documented LA dilation (LA diameter >=45 mm for men
                  and >=40 mm for women)

          5. Written informed consent to participate in the study prior to any study procedures

        Exclusion Criteria:

          1. Need for a continuous treatment with ARBs for any clinical reasons

          2. Contraindications or known hypersensitivity to ARBs

          3. Persistent standing systolic blood pressure < 110 mmHg

          4. Recent (<6 weeks) acute myocardial infarction or bypass surgery, or percutaneous
             coronary intervention

          5. Clinically significant valvular etiologies

          6. Thyroid dysfunction

          7. Indication for pacemaker or ICD implant or for an ablative treatment, recent (<6
             months) PM or ICD implant, previous ablative treatment

          8. Planned cardiac surgery, expected to be performed within 3 months

          9. Serum creatinine level above 2.5 mg/dL

         10. Significant liver disease

         11. Pregnant or lactating women or women of childbearing potential who are not protected
             from pregnancy by an accepted method of contraception

         12. Any condition that in the opinion of the investigator would jeopardize the evaluation
             of efficacy or safety or be associated with poor adherence to the protocol

         13. Presence of any non-cardiac disease (e.g. cancer) that is likely to significantly
             shorten life expectancy

         14. Treatment with any investigational agent within 1 month before randomization

         15. Currently decompensated heart failure
Clinical trial NCT00035802 (phase 3, status: completed)
Conditions: bipolar disorder, affective disorders, psychotic, mood disorders, mental disorders
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32, F34.81, F39, F34.9, F43.21, F10.14, F10.24, F11.14, F48.9, F99, F51.05, F51.13, F09, F06.8, F48.8
Drugs: topiramate, placebo
SMILES: [H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  DSM-IV diagnosis of Bipolar I Disorder (confirmed by the Kiddie-Schedule for Affective
             Disorders and Schizophrenia-Present and Lifetime version [K-SADS-P/L])

          -  YMRS score greater than or equal to 20

          -  General good health as determined by medical history, physical examination, and
             laboratory evaluations

          -  Ability to swallow tablets

          -  Patient's parent or guardian must be fully capable of monitoring the patient's disease
             process and compliance to treatment

          -  Parent(s) or legal guardian(s) must read and sign the informed consent form after the
             nature of the study has been fully explained and assent must be obtained from patients

        Exclusion Criteria:

          -  DSM-IV Axis I disorder diagnoses of autistic disorder, schizophrenia, schizoaffective
             disorder, or other psychotic disorders not otherwise specified (NOS)

          -  DSM-IV diagnosis of alcohol or substance dependence, with the exception of nicotine or
             caffeine dependence, within the 3 months prior to baseline. Acute or intermittent
             substance abuse prior to screening will not be exclusionary, depending upon the
             clinical judgment of the investigator

          -  Chronic antidepressant treatment within 4 weeks of randomization (5 weeks for
             fluoxetine), use of psychostimulants in the 7 days prior to baseline, use of any other
             psychotropic medications within 3 days or 5 half-lives, whichever is less, prior to
             baseline, or requirement for treatment with other psychotropic drugs on an ongoing
             basis

          -  Weight less than 33 kg or current or past history of anorexia nervosa

          -  Serious or unstable medical or neurological conditions